Летонија - Летонски - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - solifencīna sukcināts - apvalkotā tablete - 5 mg

Летонија - Летонски - Zāļu valsts aģentūra

astellas pharma d.o.o., slovenia - solifencīna sukcināts - suspensija iekšķīgai lietošanai - 1 mg/ml

Летонија - Летонски - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - bortezomibs - pulveris injekciju šķīduma pagatavošanai - 3,5 mg

Летонија - Летонски - Zāļu valsts aģentūra

medochemie ltd., cyprus - solifencīna sukcināts - apvalkotā tablete - 5 mg

Европска Унија - Летонски - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, aknu - dažādi gremošanas traktu un vielmaiņu ietekmējošie līdzekļi - Ārstēšana akūtas aknu porphyria (ahp) pieaugušajiem un pusaudžiem vecumā no 12 gadiem un vecāki.

Летонија - Летонски - Zāļu valsts aģentūra

stada arzneimittel ag, germany - bortezomibs - Šķīdums injekcijām - 2,5 mg/ml

Летонија - Летонски - Zāļu valsts aģentūra

mylan healthcare b.v., netherlands - didrogesterons - apvalkotā tablete - 10 mg

Европска Унија - Летонски - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - un imūnglobulīni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. skatīt nodaļas 4. 4 un 5.

Летонија - Летонски - Zāļu valsts aģentūra

mylan healthcare b.v., netherlands - didrogesterons - apvalkotā tablete - 10 mg

Европска Унија - Летонски - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.